INS and type 2 diabetes mellitus: The data showed significant improvement in β-cell function and glycemic control, as assessed by fasting, postprandial, and overall (AUC0–24h) glucose and glucagon responses, as well as insulin secretion rate, among those with T2D who received semaglutide.